Psychopharmacology

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Review the developments in GLP-1s in 2026.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

Psychiatrists admit carrying benzos for travel sleep or anxiety; learn why experts say occasional use differs from dependence and withdrawal risk.

HLP003, a deuterated psilocin agonist, enters phase 3 as an add-on for MDD, aiming to boost SSRI/SNRI response earlier.

A quick recap of the last week in psychiatric news.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Psychiatrists rebut antidepressant myths, outlining modest benefits, real but manageable risks, and why slow tapering matters for withdrawal.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Experts unpack when benzodiazepines help or harm, tapering myths, older-adult risks, and why Alzheimer links may be overstated.

Michael Thase, MD, explores evolving treatment strategies for treatment-resistant depression, including interventional psychiatry and emerging therapies.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.

Review the latest developments in narcolepsy treatment.

Review the latest in psychiatry from the last week.

FDA approves Takeda’s Orzeyful, first orexin agonist, improving wakefulness and reducing cataplexy in adults with narcolepsy type 1 in pivotal trials.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

New ADHD option Simtriyo gains FDA approval as first NDSRI, showing benefits for teens and adults, including executive function and emotional control.

Learn how clinicians reframe side effects, curb nocebo, and boost outcomes using expectation, open-label placebos, and conditioning in psychiatry.

New Alzheimer trial news highlights safer anti-amyloid PMN310, cannabinoids easing agitation, tau gene therapy progress, FDA Fast Track psychosis drug, and TBI inflammation targets.

Experts discuss the impact of the placebo effect on psychiatric treatment outcomes.